EN DE
Watch CORESTEM Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

CORESTEM Inc (166480) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of CORESTEM Inc stock KRW 1,233, price KRW 1,363, that is 9.6% below the price, quality 14 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7166480004

CI CORESTEM Inc logo Thin data Nov 16, 2026

CORESTEM Inc

166480 · KQ

Expensive (fair value 10% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Low debt 
Fair value 1,233 KRW · Overvalued 
Quality 14/100 
Weak Growth (revenue 5y −5.2 %/yr in KRW) 
Loss-making · -152.0% net margin (TTM) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 9/100
Thin data 
Estimate
Watch CORESTEM Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

19,338 KRW 1,060 KRW Fair Value 1,233 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,060 KRW – 19,338 KRW · fair‑value band 924.41 KRW – 1,541 KRW · the 1,363 KRW price screens above the 1,233 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow CORESTEM in your weekly email

Every Wednesday you see whether CORESTEM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea.

Show moreShow less

It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.

The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.

Stock analysis

CORESTEM Inc (166480) currently trades at 1,363 KRW, while our estimate is 1,233 KRW, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 924.41 KRW (bear) to 1,541 KRW (bull), the price of 1,363 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

CORESTEM Inc reported revenue of 20.2B KRW in FY2025 versus 30.2B KRW in FY2021, a compound −9.6%/yr. Reported net income was −26.8B KRW in FY2025.

Key figures

Market cap 66.8B KRW (≈ $50.2M) Micro · P/S ratio 4.57 · EPS (TTM) −578.16 KRW · Net margin −133% · Return on equity −62.0% · Return on assets (EBIT) −16.2% (5-year average) · Operating margin −79.3% · Revenue (TTM) 18.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 72% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, 166480 screens richer than that median.

Fair Value

Bear 924.41 KRW Fair Value 1,233 KRW Bull 1,541 KRW
Price 1,363 KRW · Downside -9.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 14/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 47
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−29.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: +0.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.6% (2020) → −105.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

166480 screens overvalued: fair value 10% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CORESTEM Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 14 · Bottom 25%
Fair Value upside −9.6% · Above median
Profitability
Return on assets −23.9% · Below median
Net margin (12 months) −152.0% · Bottom 25%
Operating margin (12 months) −79.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.7% · Below median
Balance sheet
Debt / equity 0.21× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.21× · Cheapest 25%
P/S (12 months) 3.65× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 2
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)89 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $945.53 $1,275 +35% vs 166480
Vertex Pharmaceuticals Incorporated VRTX $536.45 $587.62 +10% vs 166480
Samsung Biologics Co 207940 1,375,000 KRW 1,502,600 KRW +9% vs 166480
argenx SE ARGX $941.25 $908.40 −3% vs 166480
CSL Limited CSL A$199.85 A$186.49 −7% vs 166480
Moderna, Inc MRNA $196.79 $135.64 −31% vs 166480
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs 166480
Revolution Medicines, Inc RVMD $159.82 $83.12 −48% vs 166480
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs 166480
Royalty Pharma plc RPRX $68.67 $19.01 −72% vs 166480

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CORESTEM Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CORESTEM Inc Fair Value". https://www.fairvalue-calculator.com/stock/166480

Frequently asked questions

Is CORESTEM Inc (166480) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,233 KRW versus a price of 1,363 KRW, about 10% lower (overvalued).
What is the fair value of 166480?
Our estimate for CORESTEM Inc is 1,233 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,363 KRW.
What is the quality score of 166480?
CORESTEM Inc has a Quality Score of 14/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CORESTEM Inc (166480)?
We do not set a price target; the yardstick is our estimate of 1,233 KRW (as of Nov 16, 2026). Cautious scenario 924.41 KRW, optimistic scenario 1,541 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CORESTEM Inc stock forecast for 2026?
Our estimate puts fair value at 1,233 KRW, about 10% lower versus a price of 1,363 KRW (overvalued). Cautious scenario 924.41 KRW, optimistic scenario 1,541 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CORESTEM Inc (166480)?
CORESTEM Inc reported trailing-twelve-month revenue of about 18.3B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of CORESTEM Inc (166480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CORESTEM Inc it is 1,233 KRW per share (as of Nov 16, 2026), against a price of 1,363 KRW.
Is CORESTEM Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 166480 trades above its calculated fair value: price 1,363 KRW, fair value 1,233 KRW, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 166480?
No. The price is what the market pays today (1,363 KRW); the fair value is what the company's own numbers justify (1,233 KRW). For CORESTEM Inc the two are 130.45 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CORESTEM Inc worth?
The market values CORESTEM Inc at about 66.8B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,363 KRW; our models calculate a fair value of 1,233 KRW per share.
What do the bullish and bearish scenarios say about 166480?
Our models span a range for CORESTEM Inc: cautious scenario 924.41 KRW, base 1,233 KRW, optimistic 1,541 KRW per share (as of Nov 16, 2026, price 1,363 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CORESTEM Inc (166480)?
Balance-sheet figures for CORESTEM Inc (as of Nov 16, 2026): return on equity −62.0%, debt of 0.21 per unit of equity. They feed the Quality Score of 14/100, which measures business quality independently of the share price.
How far is 166480 from its 52-week high?
CORESTEM Inc trades at 1,363 KRW, about 72% below its 52-week high of 4,800 KRW and 29% above the low of 1,060 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 1,233 KRW is for.
Which stocks are comparable to CORESTEM Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CORESTEM Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 1,363 KRW, calculated fair value 1,233 KRW (−10%), Quality Score 14/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. CORESTEM Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CORESTEM Inc (166480)?
The closing price on Nov 19, 2026 was 1,363 KRW. Our estimate is 1,233 KRW, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CORESTEM Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of CORESTEM Inc

How large is the market capitalisation of CORESTEM Inc (166480)?
The market capitalisation of CORESTEM Inc is 66.8B KRW (≈ $50.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CORESTEM Inc (166480)?
The price-to-sales ratio of CORESTEM Inc is 4.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CORESTEM Inc (166480)?
Earnings per share at CORESTEM Inc are −578.16 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CORESTEM Inc (166480)?
The net margin of CORESTEM Inc is −133% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CORESTEM Inc (166480)?
The return on equity (ROE) of CORESTEM Inc is −62.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CORESTEM Inc (166480)?
On an EBIT basis the return on assets of CORESTEM Inc is −16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CORESTEM Inc (166480)?
The operating margin of CORESTEM Inc is −79.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CORESTEM Inc (166480)?
Revenue at CORESTEM Inc is down 1.7% versus a year earlier (3y avg −24.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CORESTEM Inc (166480) generate?
The free cash flow of CORESTEM Inc is −15.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CORESTEM Inc (166480) carry?
The net debt of CORESTEM Inc is 35.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CORESTEM Inc in the live analysis

One click puts CORESTEM Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.